4D Molecular Therapeutics (FDMT) Earnings Date & Reports

Key Takeaways

• 4D Molecular Therapeutics is expected to report third-quarter 2026 results around November 10, 2026, with consensus estimates calling for a net loss near $1.04 per share.
• Revenue is expected to rise sharply year over year, from roughly $90,000 in the prior-year quarter to an estimated low single-digit millions, driven by Otsuka collaboration cost-sharing.
• Investors will focus less on the headline loss and more on clinical milestones for lead gene-therapy candidate 4D-150 in wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
• The pivotal 4FRONT-1 Phase 3 trial in wet AMD completed randomization (523 patients), with topline data expected in the first half of 2027.
• The company's cash position is projected to fund operations into the second half of 2028, reducing near-term dilution risk.
• For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover Trending AI Robots to explore AI-driven trading strategies for stocks like FDMT.

Earnings Context and Why It Matters

As a clinical-stage biotechnology company, 4D Molecular Therapeutics (FDMT) generates minimal product revenue, so quarterly results are defined less by profitability and more by pipeline execution and balance-sheet runway. The upcoming report matters because it arrives amid pivotal progress for 4D-150, its lead gene-therapy candidate for wet AMD and DME. With the 4FRONT-1 Phase 3 trial fully randomized and 4FRONT-2 enrollment nearing completion, investors are watching for confirmation of timelines and trial progress. Research and development (R&D) spending continues to climb as these late-stage programs advance, making cash guidance a key signal. The report offers a checkpoint on both clinical momentum and financial durability heading into a catalyst-rich 2027.

Earnings Expectations

Analysts expect 4D Molecular Therapeutics to report a net loss of roughly $1.04 per share for the third quarter of 2026, with revenue consensus estimates clustering in the low single-digit millions (around $3.5 million). That revenue figure reflects continued cost-sharing and reimbursement under the company's Otsuka collaboration rather than product sales, and it would represent a substantial increase from the approximately $90,000 recorded a year earlier.

For context, the company posted a loss of $1.04 per share in the second quarter of 2026, missing the roughly $1.01–$1.02 consensus, while revenue of $3.78 million exceeded estimates. Earnings per share (EPS) surprises have historically driven outsized moves in FDMT shares, though the far larger catalyst for this stock remains clinical data and trial-enrollment updates rather than a beat or miss on the bottom line.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotechnology names like FDMT, it offers a structured way to identify setups across the sector as earnings season unfolds.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is shaped more by the company's clinical narrative than by its financials. FDMT shares have been volatile around recent earnings releases, with modest post-earnings moves in recent quarters as investors weighed pipeline updates against widening operating losses. Heading into this report, attention is centered on any updates regarding 4FRONT-1 topline timing, 4FRONT-2 enrollment completion, and the PRISM and SPECTRA two-year data readouts. Key risk factors include potential delays in trial timelines, higher-than-expected R&D spending, and broader weakness in biotechnology and gene-therapy valuations. A reaffirmation of the cash runway into the second half of 2028 would likely provide reassurance to investors.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, the primary drivers for FDMT are clinical rather than financial. The company expects topline data from the 4FRONT-1 Phase 3 trial in wet AMD in the first half of 2027, with 4FRONT-2 topline data anticipated in the second half of 2027. These readouts represent the single most important catalysts for the stock, as they will determine whether 4D-150 can become a commercially viable gene therapy for a large ophthalmology market.

Nearer term, investors should monitor several items. Two-year data from the PRISM Phase 2b trial in wet AMD is expected to be presented at a scientific conference, and two-year SPECTRA data in DME is anticipated in the second half of 2026. The company also plans to initiate a global Phase 3 trial in DME and to share an update on its 4D-710 program for cystic fibrosis lung disease.

On the financial side, watch the trajectory of R&D expenses, which have risen sharply as late-stage trials accelerate. Management's commentary on cash runway, collaboration payments from Otsuka, and any future financing needs will be important for assessing dilution risk. As always with clinical-stage biotech, the balance between execution and capital discipline will be a central theme.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations